Stockscreener 앱 받기
3.48
3.06%
-0.11
시장 영업 전:
3.47
-0.010
-0.29%
전일 마감가:
$3.59
열려 있는:
$3.53
하루 거래량:
211.55K
Relative Volume:
0.89
시가총액:
$138.51M
수익:
$2.70M
순이익/손실:
$5.53M
주가수익비율:
31.64
EPS:
0.11
순현금흐름:
$-10.55M
1주 성능:
-1.14%
1개월 성능:
+17.97%
6개월 성능:
+61.11%
1년 성능:
+55.36%
1일 변동 폭
$3.445
$3.59
1주일 범위
$3.31
$3.65
52주 변동 폭
$1.82
$3.71
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
명칭
Oramed Pharmaceuticals Inc
전화
646-844-1164
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
ORMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.48 | 142.89M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-12 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 개시 | Canaccord Genuity | Buy |
| 2021-02-09 | 개시 | National Securities | Buy |
| 2020-12-03 | 개시 | Alliance Global Partners | Buy |
| 2020-03-11 | 개시 | Aegis Capital | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2017-12-11 | 재개 | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 재확인 | FBR Capital | Outperform |
| 2015-12-01 | 재확인 | H.C. Wainwright | Buy |
| 2015-11-19 | 개시 | FBR Capital | Outperform |
| 2015-04-13 | 재개 | MLV & Co | Buy |
| 2014-01-30 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 개시 | MLV & Co | Buy |
| 2013-12-03 | 개시 | Aegis Capital | Buy |
모두보기
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Jobs Data: Is Oramed Pharmaceuticals Inc stock good for income investors2025 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Oramed Shares Face Pressure Amid Strategic Pivot and Dividend Focus - AD HOC NEWS
Oramed Pharm completes warrant sale, boosting liquidity - MSN
Is Oramed Pharmaceuticals Inc. stock undervalued right nowVolume Analysis Techniques & Plan Every Trade With Controlled Risk - bollywoodhelpline.com
What hedge funds are buying Oramed Pharmaceuticals Inc.Recession Risk & Daily Technical Forecast Reports - bollywoodhelpline.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest - MarketBeat
Published on: 2026-01-17 10:34:33 - baoquankhu1.vn
Oramed Pharmaceuticals Inc.: - marketscreener.com
Oramed Pharm pivots with Lifeward strategic platform deal - TipRanks
Oramed Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Oramed to transfer oral drug delivery platform to Lifeward By Investing.com - Investing.com Nigeria
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal - Investing.com Nigeria
Buyout Rumor: Can Oramed Pharmaceuticals Inc maintain sales growthQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Oramed And Lifeward Reveal Strategic Deal - Pulse 2.0
Oramed to transfer oral drug delivery platform to Lifeward - Investing.com India
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal By Investing.com - Investing.com South Africa
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - manilatimes.net
Oramed and Lifeward Announce Strategic Transaction - Nasdaq
Upcoming Events - FinancialContent
Lifeward Ltd. announced that it expects to receive $20 million in funding from Oramed Pharmaceuticals Inc. - marketscreener.com
Oramed Announces Shareholder Capital Return Following Strategic Windfall - AD HOC NEWS
Take Profit: Will Oramed Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Intraday Action & Growth Focused Investment Plans - Улправда
Why Oramed Pharmaceuticals Inc. stock could outperform in 2025Trade Performance Summary & Risk Managed Investment Entry Signals - Улправда
Is Oramed Pharmaceuticals Inc. stock a buy in volatile markets2025 Retail Activity & Daily Volume Surge Signals - ulpravda.ru
Will Oramed Pharmaceuticals Inc. stock outperform value stocks2025 Key Lessons & Intraday High Probability Alerts - ulpravda.ru
Oramed Pharmaceuticals Inc. Declares Dividend of $0.25 (NASDAQ:ORMP) - MarketBeat
Oramed inks deal with Medicox for oral insulin in South Korea - The Pharma Letter
Is Oramed Pharmaceuticals Inc. (OJU1) stock suitable for passive index fundsMarket Sentiment Shifts & Outstanding Capital Returns - Улправда
MSN Money - MSN
Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026 - MarketScreener
Oramed stock rises after receiving $18 million payment from Scilex By Investing.com - Investing.com Nigeria
Oramed receives $18 million payment from Scilex, declares dividend By Investing.com - Investing.com Nigeria
Oramed Pharm Announces Dividend After Scilex Payment Gain - TipRanks
Oramed receives $18 million payment from Scilex, declares dividend - Investing.com
Oramed Pharmaceuticals Inc Receives $18 Million Payment and Approves Dividend - TradingView
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - Barchart.com
What analysts say about Oramed Pharmaceuticals Inc stockLow Beta Stocks & Breakthrough Profit Margins - earlytimes.in
Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation - TipRanks
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years - Investing.com
Oramed Pharmaceuticals completes $28.5 million warrant repurchase by Scilex - Investing.com Nigeria
Oramed Pharm Completes Warrant Sale, Boosting Liquidity - TipRanks
Oramed Pharmaceuticals Completes Warrant Repurchase with Scilex - TradingView — Track All Markets
Scilex Holding completes $27 million repurchase of warrants from Oramed By Investing.com - Investing.com South Africa
Scilex Holding completes $27 million repurchase of warrants from Oramed - Investing.com
Oramed Pharmaceuticals Inc (ORMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):